Business
Launch of SlimBiome® in North America
Launch of SlimBiome® in North America.
About this update from Optibiotix Health Plc
[{"type":"text","content":"\n \nRNS Number : 4825B OptiBiotix Health PLC 31 January 2020 \n\n31 January 2020\nOptiBiotix Health plc\n(\"OptiBiotix\" or the \"Company\")\n \nLaunch of SlimBiome® in North America with Agropur Inc.\n \nOptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, and Agropur Inc. (\"Agropur\") have announced the launch of SlimBiome in the North American market. This launch follows the announcement (RNS: 24 June 2019) that OptiBiotix granted Agropur an exclusive license to manufacture, supply and distribute OptiBiotix's SlimBiome® weight management technology in the USA, Canada and Mexico. \nAgropur is a wholly owned subsidiary of Agropur Cooperative, which is a North American dairy industry leader founded in 1938. With 8,800 employees and sales of US$5.5 billion in 2019, Agropur processes more than 14 billion lbs of milk per year at its 38 plants across North America. \nMike Homewood, Vice President of Agropur Custom Solutions, said, \"We are proud of our agreement and partnership with OptiBiotix and the exclusive opportunity to bring SlimBiome® to the North American food and nutrition industries. This ingredient solution for weight management fits into Agropur's goal to provide innovative, forward-thinking products to our customers.\"\n \nDr. Fred Narbel, Managing Director of OptiBiotix's prebiotics division, commented, \"We are very pleased with the progress Agropur has made since the announcement of our partnership at the end of June 2019. Over a rather short period of time, Agropur has qualified its manufacturing process and is now able to produce SlimBiome® in the USA and supply the ingredient to North American B2B customers. This is a key strategic step In OptiBiotix's commercial development as it grants the company access to the US weight management market which was estimated to be worth US$72 billion in 2019 (source: BusinessWire.com).\"\n \nFor further information, please contact:\n \n\n\n\nOptiBiotix Health plc\n\n\nwww.optibiotix.com\n\n\n\n\nStephen O'Hara, Chief Executive\n\n\nContact via Walbrook below\n\n\n\n\n\n\n\n\n\n\n\n\nfinnCap (Broker)\n\n\nTel: 020 7220 0500\n\n\n\n\nGeoff Nash / Kate Bannatyne (Corporate Finance)\n\n\n\n\n\n\n\nCamille Gochez (Corporate Broking)\n\n\n \n\...